Percutaneous cryoablation of solitary sporadic renal cell carcinomas

Grant D. Schmit, R. Houston Thompson, Anil N. Kurup, Adam J. Weisbrod, Rickey E. Carter, Matthew R Callstrom, Thomas D. Atwell

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

OBJECTIVE • To evaluate retrospectively our single institution experience with percutaneous cryoablation of solitary, sporadic renal cell carcinomas (RCCs), and to compare the efficacy and safety of this technique for treatment of different T-stage RCC. PATIENTS AND METHODS • 116 patients were treated with percutaneous cryoablation for a solitary, sporadic biopsy-proven RCC in a single treatment session between November 2003 and November 2010. • The technical success of the ablation procedure, complications and evidence for local or metastatic tumour recurrence were evaluated for each patient. RESULTS • 83 patients (72%) were treated for a stage T1a RCC, 27 patients (23%) for a stage T1b RCC, and six patients (5%) for a stage T2 RCC. • Technical success was achieved in the treatment of 115 of 116 (99%) renal tumours. The single technical failure occurred in the treatment of a 4.3-cm RCC. • Local recurrent tumour was identified in one of 88 patients (1%) with follow-up computed tomography (CT) or magnetic resonance imaging available for review > 3 months from the time of ablation. The median (range) imaging follow-up in these patients was 21 (3 - 73) months. The local tumour recurrence was identified on CT 11 months after the ablation procedure in a patient treated for a 2.7 cm RCC. • None of the patients developed metastatic RCC. • The major complication rate was 4% for patients with stage T1a tumours, 15% for those with stage T1b tumours, and 33% for those with stage T2 tumours. There were no procedural-related deaths. CONCLUSIONS • Percutaneous renal cryoablation of RCC can be performed with high technical success in patients with tumours up to, and beyond 7 cm in maximum diameter. • The tumour recurrence rate after percutaneous renal cryoablation was low, and recurrence was not related to tumour size in this group of patients. • Statistically significant higher complication rates were seen with treatment of larger (higher T-stage) RCCs.

Original languageEnglish (US)
JournalBJU International
Volume110
Issue number11 B
DOIs
StatePublished - Dec 2012

Fingerprint

Cryosurgery
Renal Cell Carcinoma
Neoplasms
Recurrence
Kidney
Tomography
Therapeutics

Keywords

  • Ablation techniques
  • Assessment
  • Kidney
  • Outcomes

ASJC Scopus subject areas

  • Urology

Cite this

Percutaneous cryoablation of solitary sporadic renal cell carcinomas. / Schmit, Grant D.; Thompson, R. Houston; Kurup, Anil N.; Weisbrod, Adam J.; Carter, Rickey E.; Callstrom, Matthew R; Atwell, Thomas D.

In: BJU International, Vol. 110, No. 11 B, 12.2012.

Research output: Contribution to journalArticle

Schmit, Grant D. ; Thompson, R. Houston ; Kurup, Anil N. ; Weisbrod, Adam J. ; Carter, Rickey E. ; Callstrom, Matthew R ; Atwell, Thomas D. / Percutaneous cryoablation of solitary sporadic renal cell carcinomas. In: BJU International. 2012 ; Vol. 110, No. 11 B.
@article{631e942a4d224e56b30194ac3f8a575d,
title = "Percutaneous cryoablation of solitary sporadic renal cell carcinomas",
abstract = "OBJECTIVE • To evaluate retrospectively our single institution experience with percutaneous cryoablation of solitary, sporadic renal cell carcinomas (RCCs), and to compare the efficacy and safety of this technique for treatment of different T-stage RCC. PATIENTS AND METHODS • 116 patients were treated with percutaneous cryoablation for a solitary, sporadic biopsy-proven RCC in a single treatment session between November 2003 and November 2010. • The technical success of the ablation procedure, complications and evidence for local or metastatic tumour recurrence were evaluated for each patient. RESULTS • 83 patients (72{\%}) were treated for a stage T1a RCC, 27 patients (23{\%}) for a stage T1b RCC, and six patients (5{\%}) for a stage T2 RCC. • Technical success was achieved in the treatment of 115 of 116 (99{\%}) renal tumours. The single technical failure occurred in the treatment of a 4.3-cm RCC. • Local recurrent tumour was identified in one of 88 patients (1{\%}) with follow-up computed tomography (CT) or magnetic resonance imaging available for review > 3 months from the time of ablation. The median (range) imaging follow-up in these patients was 21 (3 - 73) months. The local tumour recurrence was identified on CT 11 months after the ablation procedure in a patient treated for a 2.7 cm RCC. • None of the patients developed metastatic RCC. • The major complication rate was 4{\%} for patients with stage T1a tumours, 15{\%} for those with stage T1b tumours, and 33{\%} for those with stage T2 tumours. There were no procedural-related deaths. CONCLUSIONS • Percutaneous renal cryoablation of RCC can be performed with high technical success in patients with tumours up to, and beyond 7 cm in maximum diameter. • The tumour recurrence rate after percutaneous renal cryoablation was low, and recurrence was not related to tumour size in this group of patients. • Statistically significant higher complication rates were seen with treatment of larger (higher T-stage) RCCs.",
keywords = "Ablation techniques, Assessment, Kidney, Outcomes",
author = "Schmit, {Grant D.} and Thompson, {R. Houston} and Kurup, {Anil N.} and Weisbrod, {Adam J.} and Carter, {Rickey E.} and Callstrom, {Matthew R} and Atwell, {Thomas D.}",
year = "2012",
month = "12",
doi = "10.1111/j.1464-410X.2012.11230.x",
language = "English (US)",
volume = "110",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "11 B",

}

TY - JOUR

T1 - Percutaneous cryoablation of solitary sporadic renal cell carcinomas

AU - Schmit, Grant D.

AU - Thompson, R. Houston

AU - Kurup, Anil N.

AU - Weisbrod, Adam J.

AU - Carter, Rickey E.

AU - Callstrom, Matthew R

AU - Atwell, Thomas D.

PY - 2012/12

Y1 - 2012/12

N2 - OBJECTIVE • To evaluate retrospectively our single institution experience with percutaneous cryoablation of solitary, sporadic renal cell carcinomas (RCCs), and to compare the efficacy and safety of this technique for treatment of different T-stage RCC. PATIENTS AND METHODS • 116 patients were treated with percutaneous cryoablation for a solitary, sporadic biopsy-proven RCC in a single treatment session between November 2003 and November 2010. • The technical success of the ablation procedure, complications and evidence for local or metastatic tumour recurrence were evaluated for each patient. RESULTS • 83 patients (72%) were treated for a stage T1a RCC, 27 patients (23%) for a stage T1b RCC, and six patients (5%) for a stage T2 RCC. • Technical success was achieved in the treatment of 115 of 116 (99%) renal tumours. The single technical failure occurred in the treatment of a 4.3-cm RCC. • Local recurrent tumour was identified in one of 88 patients (1%) with follow-up computed tomography (CT) or magnetic resonance imaging available for review > 3 months from the time of ablation. The median (range) imaging follow-up in these patients was 21 (3 - 73) months. The local tumour recurrence was identified on CT 11 months after the ablation procedure in a patient treated for a 2.7 cm RCC. • None of the patients developed metastatic RCC. • The major complication rate was 4% for patients with stage T1a tumours, 15% for those with stage T1b tumours, and 33% for those with stage T2 tumours. There were no procedural-related deaths. CONCLUSIONS • Percutaneous renal cryoablation of RCC can be performed with high technical success in patients with tumours up to, and beyond 7 cm in maximum diameter. • The tumour recurrence rate after percutaneous renal cryoablation was low, and recurrence was not related to tumour size in this group of patients. • Statistically significant higher complication rates were seen with treatment of larger (higher T-stage) RCCs.

AB - OBJECTIVE • To evaluate retrospectively our single institution experience with percutaneous cryoablation of solitary, sporadic renal cell carcinomas (RCCs), and to compare the efficacy and safety of this technique for treatment of different T-stage RCC. PATIENTS AND METHODS • 116 patients were treated with percutaneous cryoablation for a solitary, sporadic biopsy-proven RCC in a single treatment session between November 2003 and November 2010. • The technical success of the ablation procedure, complications and evidence for local or metastatic tumour recurrence were evaluated for each patient. RESULTS • 83 patients (72%) were treated for a stage T1a RCC, 27 patients (23%) for a stage T1b RCC, and six patients (5%) for a stage T2 RCC. • Technical success was achieved in the treatment of 115 of 116 (99%) renal tumours. The single technical failure occurred in the treatment of a 4.3-cm RCC. • Local recurrent tumour was identified in one of 88 patients (1%) with follow-up computed tomography (CT) or magnetic resonance imaging available for review > 3 months from the time of ablation. The median (range) imaging follow-up in these patients was 21 (3 - 73) months. The local tumour recurrence was identified on CT 11 months after the ablation procedure in a patient treated for a 2.7 cm RCC. • None of the patients developed metastatic RCC. • The major complication rate was 4% for patients with stage T1a tumours, 15% for those with stage T1b tumours, and 33% for those with stage T2 tumours. There were no procedural-related deaths. CONCLUSIONS • Percutaneous renal cryoablation of RCC can be performed with high technical success in patients with tumours up to, and beyond 7 cm in maximum diameter. • The tumour recurrence rate after percutaneous renal cryoablation was low, and recurrence was not related to tumour size in this group of patients. • Statistically significant higher complication rates were seen with treatment of larger (higher T-stage) RCCs.

KW - Ablation techniques

KW - Assessment

KW - Kidney

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84876434715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876434715&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2012.11230.x

DO - 10.1111/j.1464-410X.2012.11230.x

M3 - Article

C2 - 22584010

AN - SCOPUS:84876434715

VL - 110

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 11 B

ER -